APTO Logo

Aptose Biosciences Inc. (APTO) 

NASDAQ
Market Cap
$4.78M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
437 of 774
Rank in Industry
225 of 432

Largest Insider Buys in Sector

APTO Stock Price History Chart

APTO Stock Performance

About Aptose Biosciences Inc.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops …

Insider Activity of Aptose Biosciences Inc.

Over the last 12 months, insiders at Aptose Biosciences Inc. have bought $0 and sold $0 worth of Aptose Biosciences Inc. stock.

On average, over the past 5 years, insiders at Aptose Biosciences Inc. have bought $202,140 and sold $1.43M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 17,000 shares for transaction amount of $53,380 was made by Seizinger Bernd R. (director) on 2023‑09‑22.

List of Insider Buy and Sell Transactions, Aptose Biosciences Inc.

2023-09-22Purchasedirector
17,000
0.2389%
$3.14$53,380-46.38%
2022-06-06PurchaseChair, President & CEO
10,000
0.0109%
$0.97$9,681-32.29%
2021-12-20Purchasedirector
10,000
0.0117%
$1.45$14,490-38.49%
2021-12-16Purchasedirector
100,000
0.1055%
$1.38$137,900-41.50%
2021-12-16PurchaseChair, President & CEO
13,183
0.0153%
$1.52$20,038-41.50%
2021-12-15Purchasedirector
270,000
0.2989%
$1.17$316,340-27.73%
2021-12-15PurchaseChair, President & CEO
17,822
0.0189%
$1.12$19,961-27.73%
2021-11-26PurchaseChair, President & CEO
8,643
0.0098%
$2.31$19,965-57.89%
2021-11-19PurchaseSr. VP, Chief Medical Officer
10,000
0.0115%
$2.56$25,600-59.76%
2021-08-05Sale10 percent owner
60,000
0.0677%
$2.62$157,200-51.72%
2021-08-03Purchase10 percent owner
57,199
0.0647%
$2.65$151,406-51.52%
2021-07-02PurchaseChair, President & CEO
6,081
0.0067%
$3.29$19,998-57.78%
2021-06-22Saledirector
9,600
0.0106%
$3.24$31,104-55.59%
2021-06-21Saledirector
15,400
0.0174%
$3.35$51,590-55.56%
2020-12-22Saledirector
20,000
0.0234%
$4.06$81,200-20.52%
2020-07-10SaleChair, President & CEO
168,891
0.1977%
$6.05$1.02M-16.11%
2020-07-10SaleExecutive VP & CFO
126,668
0.1483%
$6.05$766,341-16.11%
2020-07-10SaleSenior VP, Chief Bus. Officer
62,835
0.0735%
$6.05$380,152-16.11%
2020-07-02SaleSenior VP, Chief Bus. Officer
20,946
0.0238%
$6.34$132,793-22.08%
2020-06-24Saledirector
17,000
0.0228%
$6.74$114,660-22.50%

Insider Historical Profitability

<0.0001%
Wilson Donald R. Jr.10 percent owner
8888275
45.5314%
$0.2511<0.0001%
PLATZER ERICHdirector
505000
2.5869%
$0.2531<0.0001%
Rice William G.Chair, President & CEO
353252
1.8096%
$0.2591+2.47%
Chow Gregory K.Executive VP & CFO
232846
1.1928%
$0.2521+46.02%
BURGER DENIS Rdirector
31671
0.1622%
$0.2510<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Annandale Capital$44,000.000.1526,666-64.29%-$79,201.980.01
Caldwell Sutter Capital Inc$153.00<0.01920%+$0<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.